Letairis and Lopinavir and Ritonavir Solution
Determining the interaction of Letairis and Lopinavir and Ritonavir Solution and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Ritonavir may increase the blood levels and effects of ambrisentan. This can increase the risk of serious side effects such as liver damage, anemia, and fluid accumulation (particularly in the lungs). You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor immediately if you experience fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. Also seek medical attention if you develop paleness, dizziness, fainting, swelling, unusual weight gain, difficulty breathing, and/or shortness of breath. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: In vitro data suggest that coadministration with potent inhibitors of P-glycoprotein (e.g., cyclosporine) and/or organic anion transporting polypeptide (e.g., cyclosporine, ritonavir) may increase the plasma concentrations of ambrisentan, which is a substrate of these transporters. In healthy volunteers, steady-state coadministration of ambrisentan and cyclosporine resulted in a 2-fold increase in ambrisentan exposure. The interaction has not been studied with other P-gp or OATP inhibitors.
MANAGEMENT: Because ambrisentan is associated with dose-related hepatotoxicity, concomitant use with potent inhibitors of P-gp and/or OATP should be approached with caution. Patients should be advised to notify their physician if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.
- "Product Information. Letairis (ambrisentan)." Gilead Sciences, Foster City, CA.
Generic Name: lopinavir / ritonavir
Brand name: Kaletra
Synonyms: Lopinavir and ritonavir, Lopinavir and Ritonavir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Letairis-Lopinavir and Ritonavir Tablets
- Letairis-Lopreeza
- Letairis-Lopressor
- Letairis-Lopressor (Metoprolol Injection)
- Letairis-Lopressor (Metoprolol Tablets)
- Letairis-Lopressor HCT
- Lopinavir and Ritonavir Solution-Letermovir
- Lopinavir and Ritonavir Solution-Letermovir Injection
- Lopinavir and Ritonavir Solution-Letermovir Intravenous
- Lopinavir and Ritonavir Solution-Letermovir oral/injection
- Lopinavir and Ritonavir Solution-Letermovir Tablets
- Lopinavir and Ritonavir Solution-Letrozole